Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2

Gastroenterology

Volumn 130, Issue 1, 2006, Pages 55-64

  Fries, Susanne ^a   Grosser, Tilo ^a   Price, Thomas S ^a   Lawson, John A ^a   Kapoor, Shiv ^a   Demarco, Susan ^a   Pletcher, Mathew T ^b   Wiltshire, Tim ^b   Fitzgerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Genomic Inst of the Novartis Found   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; PLACEBO; ROFECOXIB;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG RESPONSE; DRUG SELECTIVITY; EX VIVO STUDY; FEMALE; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 30044436433     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.10.002     Document Type: Article

References (48)

1. G.A. FitzGerald, C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442
2. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M.B. Ferraz, C.J. Hawkey, M.C. Hochberg, T.K. Kvien, T.J. Schnitzer Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 2000 1520 1530
3. T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, E. Ehrsam, X. Gitton, G. Krammer, B. Mellein, P. Matchaba, A. Gimona, C.J. Hawkey Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications randomised controlled trial Lancet 364 2004 665 674
4. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L.K. Su, B. Levin The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
5. E. Ott, N.A. Nussmeier, P.C. Duke, R.O. Feneck, R.P. Alston, M.C. Snabes, R.C. Hubbard, P.H. Hsu, L.J. Saidman, D.T. Mangano Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery J Thorac Cardiovasc Surg 125 2003 1481 1492
6. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, M. Bertagnolli Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080
7. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, M.A. Konstam, J.A. Baron Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
8. N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, S.W. Boyce, K.M. Verburg Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 352 2005 1081 1091
9. S. Tacconelli, M.L. Capone, M.G. Sciulli, E. Ricciotti, P. Patrignani The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity Curr Med Res Opin 18 2002 503 511
10. B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, G.A. FitzGerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2 the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci U S A 96 1999 272 277
11. F. Catella-Lawson, B. McAdam, B.W. Morrison, S. Kapoor, D. Kujubu, L. Antes, K.C. Lasseter, H. Quan, B.J. Gertz, G.A. FitzGerald Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J Pharmacol Exp Ther 289 1999 735 741
12. 2 Science 296 2002 539 541
13. Z. Qi, C.M. Hao, R.I. Langenbach, R.M. Breyer, R. Redha, J.D. Morrow, M.D. Breyer Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II J Clin Invest 110 2002 61 69
14. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice J Clin Invest 114 2004 784 794
15. G.A. FitzGerald COX-2 and beyond approaches to prostaglandin inhibition in human disease Nat Rev Drug Discov 2 2003 879 890
16. G.A. FitzGerald Coxibs and cardiovascular disease N Engl J Med 351 2004 1709 1711
17. C.D. Furberg, B.M. Psaty, G.A. FitzGerald Parecoxib, valdecoxib, and cardiovascular risk Circulation 111 2005 249
18. E. Israel, V.M. Chinchilli, J.G. Ford, H.A. Boushey, R. Cherniack, T.J. Craig, A. Deykin, J.K. Fagan, J.V. Fahy, J. Fish, M. Kraft, S.J. Kunselman, S.C. Lazarus, R.F. Lemanske Jr, S.B. Liggett, R.J. Martin, N. Mitra, S.P. Peters, E. Silverman, C.A. Sorkness, S.J. Szefler, M.E. Wechsler, S.T. Weiss, J.M. Drazen Use of regularly scheduled albuterol treatment in asthma genotype-stratified, randomised, placebo-controlled cross-over trial Lancet 364 2004 1505 1512
19. A.J. Wood Racial differences in the response to drugs - pointers to genetic differences N Engl J Med 344 2001 1394 1396
20. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, S.N. Vyas, G.A. FitzGerald Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
21. P. Patrignani, P. Filabozzi, C. Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J Clin Invest 69 1982 1366 1372
22. M.R. Panara, G. Renda, M.G. Sciulli, G. Santini, M. Di Giamberardino, M.T. Rotondo, S. Tacconelli, F. Seta, C. Patrono, P. Patrignani Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects J Pharmacol Exp Ther 290 1999 276 280
23. G.A. FitzGerald, A.K. Pedersen, C. Patrono Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease Circulation 67 1983 1174 1177
24. 2 metabolites in humans Thromb Res 47 1987 647 656
25. T. Wiltshire, M.T. Pletcher, S. Batalov, S.W. Barnes, L.M. Tarantino, M.P. Cooke, H. Wu, K. Smylie, A. Santrosyan, N.G. Copeland, N.A. Jenkins, F. Kalush, R.J. Mural, R.J. Glynne, S.A. Kay, M.D. Adams, C.F. Fletcher Genome-wide single-nucleotide polymorphism analysis defines haplotype patterns in mouse Proc Natl Acad Sci U S A 100 2003 3380 3385
26. J. Yan, J. Fine Estimating equations for association structures Stat Med 23 2004 859 880
27. D.J. Spiegelhalter, A. Thomas, N.G. Best WinBUGS Version 1.2 User Manual. Technical manual 1999 MRC Biostatistics Unit Cambridge, UK Available at: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml. Accessed November 28, 2005
28. C. Patrono, P. Patrignani, L.A. Garcia Rodriguez Cyclooxygenase-selective inhibition of prostanoid formation transducing biochemical selectivity into clinical read-outs J Clin Invest 108 2001 7 13
29. 2 J Clin Invest 102 1998 1994 2001
30. H. Francois, K. Athirakul, L. Mao, H. Rockman, T.M. Coffman Role for thromboxane receptors in angiotensin-II-induced hypertension Hypertension 43 2004 364 369
31. A.J. Cayatte, Y. Du, J. Oliver-Krasinski, G. Lavielle, T.J. Verbeuren, R.A. Cohen The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice evidence that eicosanoids other than thromboxane contribute to atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 1724 1728
32. K.M. Egan, J.A. Lawson, S. Fries, B. Koller, D.J. Rader, E.M. Smyth, G.A. FitzGerald COX-2 derived prostacyclin confers atheroprotection on female mice Science 360 2004 1954 1957
33. D. Wang, J.R. Mann, R.N. DuBois The role of prostaglandins and other eicosanoids in the gastrointestinal tract Gastroenterology 128 2005 1445 1461
34. K. Malmstrom, S. Daniels, P. Kotey, B.C. Seidenberg, P.J. Desjardins Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain a randomized, placebo- and active-comparator- controlled clinical trial Clin Ther 21 1999 1653 1663
35. B.W. Morrison, J. Fricke, J. Brown, W. Yuan, P. Kotey, D. Mehlisch The optimal analgesic dose of rofecoxib overview of six randomized controlled trials J Am Dent Assoc 131 2000 1729 1737
36. A. Markiewicz, K. Semenowicz Time dependent changes in the pharmacokinetics of aspirin Int J Clin Pharmacol Biopharm 17 1979 409 411
37. J. Clench, A. Reinberg, Z. Dziewanowska, J. Ghata, M. Smolensky Circadian changes in the bioavailability and effects of indomethacin in healthy subjects Eur J Clin Pharmacol 20 1981 359 369
38. FDA New Drug Application 20-998. Clinical Pharmacology and Biopharmaceutics Review Celecoxib 1998 Food and Drug Administration Bethesda, MD 1 60
39. J.B. Hogenesch, S. Panda, S. Kay, J.S. Takahashi Circadian transcriptional output in the SCN and liver of the mouse Novartis Foundation Symposium 253 2003 171 183 discussion 52-55, 102-109
40. J.M. Drazen, E.K. Silverman, T.H. Lee Heterogeneity of therapeutic responses in asthma Br Med Bull 56 2000 1054 1070
41. J. Chladek, J. Grim, J. Martinkova, M. Simkova, J. Vaniekova, V. Koudelkova, M. Noiekova Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis Br J Clin Pharmacol 54 2002 147 156
42. L. Stahle, L. Moberg, J.O. Svensson, A. Sonnerborg Efavirenz plasma concentrations in HIV-infected patients inter- and intraindividual variability and clinical effects Ther Drug Monit 26 2004 267 270
43. C.M. Ulrich, J. Bigler, J. Sibert, E.A. Greene, R. Sparks, C.S. Carlson, J.D. Potter Cyclooxygenase 1 polymorphisms in African-American and Caucasian populations Hum Mutat 20 2002 409 410
44. A. Papafili, M.R. Hill, D.J. Brull, R.J. McAnulty, R.P. Marshall, S.E. Humphries, G.J. Laurent Common promoter variant in cyclooxygenase-2 represses gene expression evidence of role in acute-phase inflammatory response Arterioscler Thromb Vasc Biol 22 2002 1631 1636
45. M.K. Halushka, L.P. Walker, P.V. Halushka Genetic variation in cyclooxygenase 1 effects on response to aspirin Clin Pharmacol Ther 73 2003 122 130
46. C. Tang, M. Shou, Q. Mei, T.H. Rushmore, A.D. Rodrigues Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor J Pharmacol Exp Ther 293 2000 453 459
47. C.R. Lee, J.A. Goldstein, J.A. Pieper Cytochrome P450 2C9 polymorphisms a comprehensive review of the in vitro and human data Pharmacogenetics 12 2002 251 263
48. M.G. Scordo, V. Pengo, E. Spina, M.L. Dahl, M. Gusella, R. Padrini Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance Clin Pharmacol Ther 72 2002 702 710